OpenAI unveiled its Atlas AI browser this week, and it’s already catching heat. Cybersecurity researchers are particularly alarmed by its integrated “agent mode,” currently limited to paying ...

George Orwell once wrote that restating the obvious is the “first duty of intelligent people.” In that vein, allow us to restate the case for what may be literacy instruction’s richest but ...

SEATTLE — A combination of a prodrug derived from C-type natriuretic peptide (CNP) called navepegritide (TransCon CNP) and a prodrug of somatropin, called lonapegsomatropin (Skytrofa), augmented the ...

As AI assistants become capable of controlling web browsers, a new security challenge has emerged: users must now trust that every website they visit won’t try to hijack their AI agent with hidden ...

The FDA has approved the once-weekly injectable lonapegsomatropin-tcgd (Skytrofa, Ascendis Pharma A/S) for replacing endogenous growth hormone in adults with growth hormone deficiency (GHD), expanding ...

What Is Skytrofa, and Why Does It Matter? Skytrofa (lonapegsomatropin-tcgd) is a long-acting version of human growth hormone (hGH). It is already approved for children with growth hormone deficiency ...

First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, ...

Lonapegsomatropin statistically significantly reduced trunk percent fat at week 38 compared with placebo (-1.7% vs 0.4%, respectively) in adult GHD patients. The Food and Drug Administration (FDA) has ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] "We are delighted to have secured TGA ...